The KINETIC phase 2 randomized controlled trial of oral pamapimod-pioglitazone in non-critically ill COVID-19 inpatients

The combination of pamapimod and pioglitazone (KIN001) has a synergetic antiviral, anti-inflammatory, and antifibrotic activity, which may prevent evolution toward COVID-19-associated severe respiratory failure. In a randomized, placebo-controlled, double-blind, phase 2, multicenter trial, 128 non-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Fumeaux, Thierry, Berger, Claudia, Bausch, Alexander, Wright, Matthew, Vilimanovich, Urosh, Soldatovic, Ivan, Vehreschild, Maria J.G.T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590811/
https://www.ncbi.nlm.nih.gov/pubmed/37876609
http://dx.doi.org/10.1016/j.isci.2023.108038

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590811/
https://www.ncbi.nlm.nih.gov/pubmed/37876609
http://dx.doi.org/10.1016/j.isci.2023.108038

Ejemplares similares